• Home
  • Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Author List
Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS
Publication
JAMA internal medicine
Publication ID (Profile URL)
https://researcherprofiles.org/profile/88521532
Publication Year
2020
PubMed ID
31816007
Publication Title
Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med. 2020 02 01; 180(2):223-230.